Kim, Min Yeung
(Department of Biochemistry, Dong-eui University College of Korean Medicine)
Ji, Seon Yeong (Department of Biochemistry, Dong-eui University College of Korean Medicine) Hwangbo, Hyun (Department of Biochemistry, Dong-eui University College of Korean Medicine) Lee, Hyesook (Department of Biochemistry, Dong-eui University College of Korean Medicine) Kim, Tae Hee (Hamsoapharm Central Research) Yoon, Seonhye (R&D Center, Naturetech Co. Ltd.) Kim, Hyun Jin (R&D Center, Naturetech Co. Ltd.) Kim, Sung Yeon (BIO Center, Chungbuk Technopark) Kim, Tae Jung (BIO Center, Chungbuk Technopark) Kim, Min Ji (BIO Center, Chungbuk Technopark) Jung, Ha Eun (BIO Center, Chungbuk Technopark) Choi, Yung Hyun (Department of Biochemistry, Dong-eui University College of Korean Medicine) |
1 | Chun, J. N., Cho, M., So, I. and Jeon, J. H. 2014. The protective effects of Schisandra chinensis fruit extract and its lignans against cardiovascular disease: a review of the molecular mechanisms. Fitoterapia 97, 224-233. DOI |
2 | Hwangbo, H., Kwon, D. H., Choi, E. O., Kim, M. Y., Ahn, K. I., Ji, S. Y., Kim, J. S., Kim, K. I., Park, N. J., Kim, B. H., Kim, G. Y., Hong, S. H., Park, C., Jeong, J. S. and Choi, Y. H. 2018. Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5alpha-reductase and androgen receptor expression in rats. Nutr. Res. Pract. 12, 378-386. DOI |
3 | Langan, R. C. 2021. Men's health: Benign prostatic hyperplasia. FP Essent. 503, 18-22. |
4 | Madersbacher, S., Sampson, N. and Culig, Z. 2019. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review. Gerontology 65, 1-7. DOI |
5 | Vafa, A., Afzal, S. M., Barnwal, P., Rashid, S., Shahid, A., Alpashree, Islam, J. and Sultana, S. 2020. Protective role of diosmin against testosterone propionate-induced prostatic hyperplasia in Wistar rats: Plausible role of oxidative stress and inflammation. Hum. Exp. Toxicol. 39, 1133-1146. DOI |
6 | Hong, G. L., Park, S. R., Jung, D. Y., Karunasagara, S., Lee, K. P., Koh, E. J., Cho, K., Park, S. S. and Jung, J. Y. 2020. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5alpha-reductase type 2. J. Ethnopharmacol. 250, 112446. DOI |
7 | Jahan, N., Chowdhury, A., Li, T., Xu, K., Wei, F. and Wang, S. 2021. Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway. Redox Rep. 26, 1-9. DOI |
8 | Kim, E. H., Brockman, J. A. and Andriole, G. L. 2018. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J. Urol. 5, 28-32. DOI |
9 | La Vignera, S., Condorelli, R. A., Russo, G. I., Morgia, G. and Calogero, A. E. 2016. Endocrine control of benign prostatic hyperplasia. Andrology 4, 404-411. DOI |
10 | Minciullo, P. L., Inferrera, A., Navarra, M., Calapai, G., Magno, C. and Gangemi, S. 2015. Oxidative stress in benign prostatic hyperplasia: a systematic review. Urol. Int. 94, 249-254. DOI |
11 | Ren, H., Li, X., Cheng, G., Li, N., Hou, Z., Suo, J., Wang, J. and Za, X. 2015. The effects of ROS in prostatic stromal cells under hypoxic environment. Aging Male 18, 84-88. DOI |
12 | Choi, Y. J., Fan, M., Tang, Y., Yang, H. P., Hwang, J. Y. and Kim, E. K. 2019. In vivo effects of polymerized anthocyanin from grape skin on benign prostatic hyperplasia. Nutrients 11, 2444. DOI |
13 | Banerjee, P. P., Banerjee, S., Brown, T. R. and Zirkin, B. R. 2018. Androgen action in prostate function and disease. Am. J. Clin. Exp. Urol. 6, 62-77. |
14 | Berger, A. P., Kofler, K., Bektic, J., Rogatsch, H., Steiner, H., Bartsch, G. and Klocker, H. 2003. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57, 57-65. DOI |
15 | Cheon, S. Y., Jin, B. R., Kim, H. J. and An, H. J. 2020. Oleanolic acid ameliorates benign prostatic hyperplasia by regulating PCNA-dependent cell cycle progression in vivo and in vitro. J. Nat. Prod. 83, 1183-1189. DOI |
16 | Dhurat, R., Sharma, A., Rudnicka, L., Kroumpouzos, G., Kassir, M., Galadari, H., Wollina, U., Lotti, T., Golubovic, M., Binic, I., Grabbe, S. and Goldust, M. 2020. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol. Ther. 33, e13379. DOI |
17 | Dong, Y., Feng, Z. L., Chen, H. B., Wang, F. S. and Lu, J. H. 2018. Corni Fructus: a review of chemical constituents and pharmacological activities. Chin. Med. 13, 34. DOI |
18 | Huang, J., Zhang, Y., Dong, L., Gao, Q., Yin, L., Quan, H., Chen, R., Fu, X. and Lin, D. 2018. Ethnopharmacology, phytochemistry, and pharmacology of Cornus officinalis Sieb. et Zucc. J. Ethnopharmacol. 213, 280-301. DOI |
19 | Halvorsen, O. J. 2008. Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers. APMIS 123, 5-62. |
20 | Heinlein, C. A. and Chang, C. 2002. Androgen receptor (AR) coregulators: An overview. Endocr. Rev. 23, 175-200. DOI |
21 | Karunasagara, S., Hong, G. L., Jung, D. Y., Kim, K. H., Cho, K. and Jung, J. Y. 2020. Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5alpha- reductase type 2 and induced cell apoptosis. PLoS One 15, e0236879. DOI |
22 | Kim, J. H., Park, K. M. and Lee, J. A. 2019. Herbal medicine for benign prostatic hyperplasia: A protocol for a systematic review of controlled trials. Medicine (Baltimore) 98, e14023. DOI |
23 | Kopustinskiene, D. M. and Bernatoniene, J. 2021. Antioxidant effects of Schisandra chinensis fruits and their active constituents. Antioxidants (Basel) 10, 620. DOI |
24 | Prajapati, A., Gupta, S., Mistry, B. and Gupta, S. 2013. Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. Biomed. Res. Int. 2013, 107954. |
25 | Li, C., Hu, W. L., Lu, M. X. and Xiao, G. F. Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway. BMC Complement. Altern. Med. 19, 233. DOI |
26 | Ma, C. H., Lin, W. L., Lui, S. L., Cai, X. Y., Wong, V. T., Ziea, E. and Zhang, Z. J. 2013. Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials. Asian J. Androl. 15, 471-482. DOI |
27 | Minutoli, L., Rinaldi, M., Marini, H., Irrera, N., Crea, G., Lorenzini, C., Puzzolo, D., Valenti, A., Pisani, A., Adamo, E. B., Altavilla, D., Squadrito, F. and Micali, A. 2016. Apoptotic pathways linked to endocrine system as potential therapeutic targets for benign prostatic hyperplasia. Int. J. Mol. Sci. 17, 1311. DOI |
28 | Rybnikar, M., Smejkal, K. and Zemlicka, M. 2019. Schisandra chinensis and its phytotherapeutical applications. Ceska. Slov. Farm. 68, 95-118. |
29 | Soulitzis, N., Karyotis, I., Delakas, D. and Spandidos, D. A. 2006. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int. J. Oncol. 29, 305-314. |
30 | Sampson, N., Koziel, R., Zenzmaier, C., Bubendorf, L., Plas, E., Jansen-Durr, P. and Berger, P. 2011. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol. Endocrinol. 25, 503-515. DOI |
31 | Sowndhararajan, K., Deepa, P., Kim, M., Park, S. J. and Kim, S. 2018. An overview of neuroprotective and cognitive enhancement properties of lignans from Schisandra chinensis. Biomed. Pharmacother. 97, 958-968. DOI |
32 | Srivilai, J., Minale, G., Scholfield, C. N. and Ingkaninan, K. 2019. Discovery of natural steroid 5 alpha-reductase inhibitors. Assay Drug Dev. Technol. 17, 44-57. DOI |
33 | Czerwinska, M. E. and Melzig, M. F. 2018. Cornus mas and Cornus Officinalis-analogies and differences of two medicinal plants traditionally used. Front. Pharmacol. 9, 894. DOI |
34 | Szopa, A., Ekiert, R. and Ekiert, H. 2017. Current knowledge of Schisandra chinensis (Turcz.) Baill. (Chinese magnolia vine) as a medicinal plant species: a review on the bioactive components, pharmacological properties, analytical and biotechnological studies. Phytochem. Rev. 16, 195-218. DOI |
35 | Thomas, D., Chughtai, B., Kini, M. and Te, A. 2017. Emerging drug therapies for benign prostatic hyperplasia. Expert. Opin. Emerg. Drugs 22, 201-212. DOI |
36 | Traish, A. M., Hassani, J., Guay, A. T., Zitzmann, M. and Hansen, M. L. 2011. Adverse side effects of 5alpha-reductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and depression in a subset of patients. J. Sex. Med. 8, 872-884. DOI |
37 | Velonas, V. M., Woo, H. H., Remedios, C. G. and Assinder, S. J. 2013. Current status of biomarkers for prostate cancer. Int. J. Mol. Sci. 14, 11034-11060. DOI |
38 | Vickman, R. E., Franco, O. E., Moline, D. C., Vander Griend, D. J., Thumbikat, P. and Hayward, S. W. 2020. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian J. Urol. 7, 191-202. DOI |
39 | Jin, B. R., Cheon, S. Y., Kim, H. J., Kim, M. S., Lee, K. H. and An, H. J. 2020. Anti-proliferative effects of standardized Cornus officinalis on benign prostatic epithelial cells via the PCNA/E2F1-dependent cell cycle pathway. Int. J. Mol. Sci. 21, 9567. DOI |
40 | Wei, F., He, X., Xu, K. and Wang, S. 2020. Stepwise frontal analysis coupled with cell membrane chromatography for affinity screening and characterization analysis of bioactive constituent from the mature fruits of schisandra chinensis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1161, 122443. DOI |
41 | Bostanci, Y., Kazzazi, A., Momtahen, S., Laze, J. and Djavan, B. 2013. Correlation between benign prostatic hyperplasia and inflammation. Curr. Opin. Urol. 23, 5-10. DOI |
42 | Li, Y., Huang, J., Lu, J., Ding, Y., Jiang, L., Hu, S., Chen, J. and Zeng, Q. 2019. The role and mechanism of Asian medicinal plants in treating skin pigmentary disorders. J. Ethnopharmacol. 245, 112173. DOI |
43 | Wu, Y., Wang, X., Shen, B., Kang, L. and Fan, E. 2013. Extraction, structure and bioactivities of the polysaccharides from Fructus corni. Recent Pat Food Nutr. Agri. 5, 57-61. DOI |
44 | Yeh, H. F., Li, T. F., Tsai, C. H., Wu, P. W., Huang, Y. H., Huang, W. J., Chen, F. J., Hwang, S. J., Chen, F. P. and Wu, T. P. 2020. The effects of a Chinese herbal medicine (VGHBPH0) on patients with benign prostatic hyperplasia: A pilot study. J. Chin. Med. Assoc. 83, 967-971. DOI |
45 | Chu, K. F., Rotker, K. and Ellsworth, P. 2013. The impact of obesity on benign and malignant urologic conditions. Postgrad. Med. 125, 53-69. |
46 | Clement, C., Witschi, U. and Kreuzer, M. 2012. The potential influence of plant-based feed supplements on sperm quantity and quality in livestock: a review. Anim. Reprod. Sci. 132, 1-10. DOI |
47 | Zhang, M., Xu, L. and Yang, H. 2018. Schisandra chinensis fructus and its active ingredients as promising resources for the treatment of neurological diseases. Int. J. Mol. Sci. 19, 1970. DOI |
48 | Zhou, Y., Men, L., Sun, Y., Wei, M. and Fan, X. 2021. Pharmacodynamic effects and molecular mechanisms of lignans from Schisandra chinensis Turcz. (Baill.), a current review. Eur. J. Pharmacol. 892, 173796. DOI |
49 | Zhou, Z., Cui, Y., Wu, J. and Jin, H. 2020. Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials. Exp. Ther. Med. 20, 1566-1574. DOI |
50 | Zhu, P., Li, J., Fu, X. and Yu, Z. 2019. Schisandra fruits for the management of drug-induced liver injury in China: A review. Phytomedicine 59, 152760. DOI |
51 | Gao, X., Liu, Y., An, Z. and Ni, J. 2021. Active components and pharmacological effects of Cornus officinalis: Literature review. Front. Pharmacol. 12, 633447. DOI |
![]() |